title: Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!
abstract: T-cell checkpoint inhibitors treat the cancer patient's immune system potentially inducing significant long-term survival. Pembrolizumab demonstrates clinical activity in patients diagnosed with melanoma and other cancers. Its mode of action suggests a rationale for combination with other treatment modalities, urging oncologists to brush up their knowledge of immunology.
authors.affiliation: BioNovion B.V., Oss, the Netherlands. a.vanelsas@bionovion.com.
authors.forename: Andrea
authors.initials: A
authors.lastname: van Elsas
authors.affiliation: BioNovion B.V., Oss, the Netherlands.
authors.forename: Hans
authors.initials: H
authors.lastname: van Eenennaam
authors.affiliation: Division of Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
authors.forename: John B
authors.initials: JB
authors.lastname: Haanen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D057170:Translational Research, Biomedical
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab